Cell Therapeutics’ Tosedostat Gets Back On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.